Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00353288 | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ | PHASE2 | COMPLETED | 446 | — | — | Mar 1, 2006 | Nov 1, 2006 | Oct 7, 2016 | 39 | France, Germany +1 |
| Name | Type | Description |
|---|---|---|
| MeMuRu-OKA (study vacc) | BIOLOGICAL | - |
| MMR, Varicella vacc (control) | BIOLOGICAL | - |
Inclusion Criteria: * Children must be healthy to participate Exclusion Criteria: * Immunosuppressive (including HIV) conditions, allergic diseases, neurological disorders, known anaphylactic reaction to MMR vaccine, and fever (axillary temperature ³ 37.5°C at the time of vaccination) are excludi...